On October 31, 2023 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023, in Dublin, Ireland (Press release, BostonGene, OCT 31, 2023, View Source [SID1234636602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Abstract number: P 420
Title: Comprehensive Molecular Profiling and Tumor Microenvironment Characteristics of Radiation-Induced Sarcoma
Presenter: Lev Bedniagin, MD, BostonGene
Category: Sarcoma Biology & ‘Omics
Date and time: Thursday, November 2, 2023 | 5:30 PM – 6:30 PM

A late-onset complication of radiotherapy, radiation-induced sarcoma (RIS), is a rare tumor associated with chemotherapy resistance and poor prognosis. Although immune checkpoint inhibitors (ICIs) are recommended for several soft tissue tumors, their efficacy has not been demonstrated in RIS. BostonGene Tumor PortraitTM testing, including whole exome sequencing (WES) and RNA-seq was performed to characterize the tumor microenvironment (TME) composition and identify genomic drivers of RIS to guide therapeutic decision-making. Over 50% of RIS patients had an IE TME subtype, which indicated the probability of a favorable response to ICI.

Click here to learn more about 2023 CTOS Annual Meeting.